When the medical industry encounters the Internet, it is like picking up a magnifying glass. At least in terms of drug traceability data, the problems are magnified in front of the public. In the "Measures for the Supervision and Administration of Drug Online Sales" announced in the first half of this year, this issue once again attracted attention, and it was emphasized in the "Measures" that online sales of prescription drugs to individual consumers are prohibited, and online sales of drugs by independent pharmacies are prohibited. . In addition, the prescription drug display function of pharmaceutical e-commerce platforms is also prohibited.
However, the so-called strictest drug supervision on online prescription sales is actually mainly due to safety issues. Because the production chain of drugs contains complex links, from production to use, they are all tied in a long chain. If there is a problem in any link, the harm will be huge and it is difficult to determine responsibility. Therefore, Liu Huadong, a researcher at the China Institute of Standardization, once said that from the current problems of counterfeit drugs and vaccines, it can be seen that the full-chain traceability system for pharmaceutical products has reached a point where it has to be built and managed.
At this moment, Yiou Health reported on September 28 that Ziyun Co., Ltd. announced today that it had signed the "Xinhuanet Medical Insurance Drug Authentication Verification Data Platform Drug Traceability Code Data Docking Agreement" with Xinhuanet .
Xinhuanet is a joint-stock company established in accordance with Chinese law. It is a comprehensive news and information service portal hosted by the state news agency Xinhua News Agency . The announcement shows that after consultation, the two parties reached a consensus on matters related to the platform for drug traceability code data query in the "medical insurance drug" verification scenario. In the future, we will work together to provide public inquiry services for medical insurance management agencies to request inquiries and verify drug information through drug traceability codes during drug and medical insurance settlement.
This means that Ziyun drug traceability data can be used as the basis for data verification by medical insurance institutions . The two parties agreed to support and cooperate with each other in the "medical insurance drug" authentication and traceability market services, which will be conducive to providing comprehensive, convenient, efficient and fast services to corporate customers such as pharmaceutical companies and merchants.
Ziyun Co., Ltd. was established in Henan in October 2002. In May 2017, Ziyun Co., Ltd. was officially listed on the National Equities Exchange and Quotations System. Ziyun has built a value provision integrated system from four major directions: consulting, software, integration, and IT service management, and is committed to high-tech services for the cutting-edge development of IT.
In terms of drug traceability data, Ziyun Co., Ltd. uses blockchain technology to realize that various data in the food and drug production and circulation processes cannot be tampered with, ensuring the trustworthiness of food and drug traceability data; through the blockchain, all parties can obtain A transparent and reliable unified information platform can check the status in real time, reduce logistics costs, trace the entire production and delivery process of items, thereby improving the efficiency of supply chain management.
Ziyun Co., Ltd. has currently created "blockchain + food and drug traceability", "Internet + smart logistics" and other platforms in the Internet of Things, mobile Internet, cloud computing, big data, and blockchain, and has developed an industry-leading A series of products based on SaaS and BaaS models. Among them, the traceability and anti-counterfeiting platform based on blockchain technology provides food and drug companies, national regulatory authorities and ordinary consumers with full-process traceable, supervised and authentic BaaS services based on one object and two codes.
Based on this strategy, Ziyun Shares has also made relevant actions recently. Yesterday, Ziyun Co., Ltd. also signed a "strategic cooperation agreement on "drug traceability and anti-counterfeiting integrated service business" with Tencent . At the same time, Ziyun shares stated that it will use the underlying technology of Tencent blockchain to build a national pharmaceutical industry blockchain alliance chain based on the Tencent blockchain BaaS open platform. Based on the underlying technology provided by Tencent blockchain, "National Pharmaceutical Industry Traceability and Anti-Counterfeiting Service Platform" and related applications provide people with a WeChat applet - "Ziyun Micro Traceability" that can be used to identify the authenticity of drugs when buying daily medicines, creating "drugs" for the world The traceability and anti-counterfeiting integrated cloud service platform "" solves drug safety issues to the greatest extent.The signing of this agreement between
Ziyun Co., Ltd. and Tencent actually marks the beginning of cooperation between
Ziyun Co., Ltd. and Tencent to enter the third-party drug traceability service market. is based on the alliance chain of the "National Pharmaceutical Industry Blockchain Alliance" to create a "drug traceability and anti-counterfeiting integrated cloud service platform" for the world, as well as a "pharmaceutical logistics shared trust and distribution service platform" based on the blockchain. It is the first in the world to realize The minimum packaging of drugs can be traced back to the logistics trajectory and temperature and humidity of the drugs, meeting the rigid demand of pharmaceutical companies for third-party drug traceability services, and meeting the policy requirements of the State Food and Drug Administration that drug traceability must achieve "one code for one item, and trace the same item code" . The signing of the
agreement lays the foundation for both parties to join hands in entering the third-party drug traceability service market, and will also have a major positive impact on Ziyun Co., Ltd.'s development of the third-party drug traceability service market. However, this layout also created unsightly data for Ziyun Co., Ltd.'s financial report.
According to Ziyun's 2018 semi-annual report, Ziyun's operating income during the reporting period was 2.3663 million yuan, a decrease of 4.66% from the same period last year; its operating costs were 2.3552 million yuan, an increase of 207.53% from the same period last year. ; The loss attributable to the parent company was 4.8717 million yuan, an increase of 101.83% compared with the same period last year. The main reasons are the increase in investment in R&D and the increase in operating costs of smart logistics in this period. In fact, Ziyun Co., Ltd. has continued to transform towards the application of cloud computing and blockchain technology following the transformation pace of the previous reporting period, with its main business focus. Provide software development and technical services for traceability, anti-counterfeiting, health management and other fields.
In fact, in order to cope with the risks brought by business transformation, while Ziyun Co., Ltd. is increasing investment in R&D and marketing, it should also speed up the pace of R&D, experimentation, and marketing, and quickly build new core competitiveness advantages in new fields.
